THE PROGNOSTIC-SIGNIFICANCE OF THE HALF-LIFE OF SERUM CA-125 IN PATIENTS RESPONDING TO CHEMOTHERAPY FOR EPITHELIAL OVARIAN-CARCINOMA

被引：62
|
作者：
HAWKINS, RE
ROBERTS, K
WILTSHAW, E
MUNDY, J
FRYATT, IJ
MCCREADY, VR
机构：
[1] ROYAL MARSDEN HOSP,DEPT MED,FULHAM RD,LONDON SW3 6JJ,ENGLAND
[2] ROYAL MARSDEN HOSP,DEPT NUCL MED,LONDON SW3 6JJ,ENGLAND
来源：
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY | 1989年 / 96卷 / 12期
关键词：
D O I：
10.1111/j.1471-0528.1989.tb06301.x
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：1395 / 1399
页数：5
相关论文
共 50 条
  • [21] Prognostic significance of normal pretreatment serum CA-125 levels in women with serous ovarian carcinoma
    Nasioudis, D.
    Frey, M. K.
    Chapman-Davis, E.
    Caputo, T. A.
    Witkin, S. S.
    Holcomb, K. M.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 63 - 63
  • [22] CA-125 HALF-LIFE IN OVARIAN-CANCER - A MULTIVARIATE SURVIVAL ANALYSIS
    YEDEMA, CA
    KENEMANS, P
    VOORHORST, F
    BON, G
    SCHIJF, C
    BEEX, L
    VERSTRAETEN, A
    HILGERS, J
    VERMORKEN, J
    BRITISH JOURNAL OF CANCER, 1993, 67 (06) : 1361 - 1367
  • [23] AN INITIAL ANALYSIS OF PREOPERATIVE SERUM CA-125 LEVELS IN PATIENTS WITH EARLY STAGE OVARIAN-CARCINOMA
    ZURAWSKI, VR
    KNAPP, RC
    EINHORN, N
    KENEMANS, P
    MORTEL, R
    OHMI, K
    BAST, RC
    RITTS, RE
    MALKASIAN, G
    GYNECOLOGIC ONCOLOGY, 1988, 30 (01) : 7 - 14
  • [24] THE CLINICAL CORRELATES OF SERUM CA125 IN 169 PATIENTS WITH EPITHELIAL OVARIAN-CARCINOMA
    HAWKINS, RE
    ROBERTS, K
    WILTSHAW, E
    MUNDY, J
    MCCREADY, VR
    BRITISH JOURNAL OF CANCER, 1989, 60 (04) : 634 - 637
  • [25] Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma
    Geisler, JP
    Miller, GA
    Lee, TH
    Harwood, RM
    Wiemann, MC
    Geisler, HE
    JOURNAL OF REPRODUCTIVE MEDICINE, 1996, 41 (03) : 140 - 142
  • [26] ELEVATION OF SERUM CA 125 PRIOR TO DIAGNOSIS OF AN EPITHELIAL OVARIAN-CARCINOMA
    BAST, RC
    SIEGAL, FP
    RUNOWICZ, C
    KLUG, TL
    ZURAWSKI, VR
    SCHONHOLZ, D
    COHEN, CJ
    KNAPP, RC
    GYNECOLOGIC ONCOLOGY, 1985, 22 (01) : 115 - 120
  • [27] CLINICAL USE OF CA-125 AND CA-19-9 IN PATIENTS WITH OVARIAN-CARCINOMA
    NEGISHI, Y
    IKEHATA, N
    AZUMA, T
    OKABE, K
    KOBAYASHI, K
    NUTAHARA, Y
    NAKAMURA, F
    SATO, H
    AKIYA, K
    TUMOUR BIOLOGY, 1986, 7 (04): : 265 - 265
  • [28] Prognostic significance of the CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV.
    Riedinger, JM
    Barillot, I
    Coudert, B
    Fargeot, P
    BerrioloRiedinger, A
    Guerrin, J
    BULLETIN DU CANCER, 1996, 83 (08) : 654 - 663
  • [29] EVALUATION OF THE CLINICAL RELEVANCE OF THE ASSAY FOR CA-125 IN THE MANAGEMENT OF PATIENTS WITH OVARIAN-CARCINOMA
    PUGH, RP
    DALBOW, MH
    RAJU, R
    ZIDAR, B
    ZAMMERILLA, CF
    TUMOUR BIOLOGY, 1985, 6 (04): : 419 - 419
  • [30] ROLE OF CA-125 AS TUMOR-MARKER IN OVARIAN-CARCINOMA
    KREBS, HB
    GOPLERUD, DR
    KILPATRICK, SJ
    MYERS, MB
    HUNT, A
    OBSTETRICS AND GYNECOLOGY, 1986, 67 (04): : 473 - 477
12345